Dirk G.  Brockstedt net worth and biography

Dirk Brockstedt Biography and Net Worth

Insider of RAPT Therapeutics
Dirk joined RAPT Therapeutics in January 2018, bringing over 20 years of experience through all stages of discovery, translational and clinical development, as well as a deep knowledge of immunology and the tumor microenvironment. He joined RAPT from Aduro Biotech, where he served as Executive Vice President of Research and Development. Prior to Aduro, Dirk held positions of increasing responsibility within the immunology department of Cerus Corporation, most recently serving as Director of Immunology. Prior to Cerus, he served as a scientist at Aventis in the immunotherapy and anti-angiogenesis group, developing novel therapies against cancer.

Dirk holds an M.S. in Microbiology from the University of Kiel, and he earned his Ph.D. from the University of Kiel (graduate work performed at Stanford University). He was a post-doctoral fellow at the Stanford School of Medicine in the Department of Pathology. He has co-authored 40 scientific papers and is a named inventor on seven issued patents and several pending applications.

What is Dirk G. Brockstedt's net worth?

The estimated net worth of Dirk G. Brockstedt is at least $249,823.60 as of January 5th, 2024. Dr. Brockstedt owns 27,820 shares of RAPT Therapeutics stock worth more than $249,824 as of March 29th. This net worth estimate does not reflect any other assets that Dr. Brockstedt may own. Additionally, Dr. Brockstedt receives an annual salary of $490,250.00 as Insider at RAPT Therapeutics. Learn More about Dirk G. Brockstedt's net worth.

How old is Dirk G. Brockstedt?

Dr. Brockstedt is currently 55 years old. There are 6 older executives and no younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics is Dr. David Wustrow, Senior Vice President of Drug Discovery & Preclinical Development, who is 65 years old. Learn More on Dirk G. Brockstedt's age.

What is Dirk G. Brockstedt's salary?

As the Insider of RAPT Therapeutics, Inc., Dr. Brockstedt earns $490,250.00 per year. There are 3 executives that earn more than Dr. Brockstedt. The highest earning executive at RAPT Therapeutics is Dr. Brian Russell Wong M.D., Ph.D., CEO, President & Director, who commands a salary of $797,500.00 per year. Learn More on Dirk G. Brockstedt's salary.

How do I contact Dirk G. Brockstedt?

The corporate mailing address for Dr. Brockstedt and other RAPT Therapeutics executives is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. RAPT Therapeutics can also be reached via phone at (650) 489-9000 and via email at [email protected]. Learn More on Dirk G. Brockstedt's contact information.

Has Dirk G. Brockstedt been buying or selling shares of RAPT Therapeutics?

Dirk G. Brockstedt has not been actively trading shares of RAPT Therapeutics during the past quarter. Learn More on Dirk G. Brockstedt's trading history.

Who are RAPT Therapeutics' active insiders?

RAPT Therapeutics' insider roster includes Dirk Brockstedt (Insider), William Ho (Insider), and Wendye Robbins (Director). Learn More on RAPT Therapeutics' active insiders.

Are insiders buying or selling shares of RAPT Therapeutics?

In the last twelve months, insiders at the sold shares 6 times. They sold a total of 14,898 shares worth more than $276,361.44. The most recent insider tranaction occured on January, 5th when insider Dirk G Brockstedt sold 898 shares worth more than $20,456.44. Insiders at RAPT Therapeutics own 5.5% of the company. Learn More about insider trades at RAPT Therapeutics.

Information on this page was last updated on 1/5/2024.

Dirk G. Brockstedt Insider Trading History at RAPT Therapeutics

See Full Table

Dirk G. Brockstedt Buying and Selling Activity at RAPT Therapeutics

This chart shows Dirk G. Brockstedt's buying and selling at RAPT Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

RAPT Therapeutics Company Overview

RAPT Therapeutics logo
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company
Read More

Today's Range

Now: $8.98
Low: $8.71
High: $9.00

50 Day Range

MA: $15.96
Low: $6.87
High: $26.45

2 Week Range

Now: $8.98
Low: $6.86
High: $27.35

Volume

860,933 shs

Average Volume

1,155,575 shs

Market Capitalization

$312.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47